tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Albuminuria D000419 18 associated lipids
Alopecia D000505 14 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amenorrhea D000568 4 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia D000740 21 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Anemia, Refractory D000753 3 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Angioedema D000799 6 associated lipids
Anus Diseases D001004 3 associated lipids
Apraxias D001072 1 associated lipids
Arm Injuries D001134 1 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Ascites D001201 25 associated lipids
Ataxia D001259 20 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Bacterial Infections D001424 21 associated lipids
Balanitis D001446 4 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Behcet Syndrome D001528 7 associated lipids
Biliary Fistula D001658 13 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Blepharitis D001762 4 associated lipids
Blindness D001766 6 associated lipids
Body Weight D001835 333 associated lipids
Bone Diseases D001847 4 associated lipids
Bradycardia D001919 13 associated lipids
Brain Diseases D001927 27 associated lipids
Brain Edema D001929 20 associated lipids
Bronchiolitis D001988 6 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Burns D002056 34 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Catalepsy D002375 30 associated lipids
Cataract D002386 34 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Cheilitis D002613 2 associated lipids
Cholelithiasis D002769 16 associated lipids
Cholestasis D002779 23 associated lipids
Choline Deficiency D002796 16 associated lipids
Hemophilia B D002836 3 associated lipids
Chronic Disease D002908 7 associated lipids
Cicatrix D002921 9 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Colitis D003092 69 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Collagen Diseases D003095 2 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Confusion D003221 4 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Corneal Diseases D003316 13 associated lipids
Cough D003371 19 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Crohn Disease D003424 12 associated lipids
Cryptococcosis D003453 3 associated lipids
Cutis Laxa D003483 1 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cystitis D003556 23 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Deglutition Disorders D003680 2 associated lipids
Dehydration D003681 11 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Cardoso CM et al. Uncoupling of Ca2+ transport ATPase in muscle and blood platelets by diacylglycerol analogues and cyclosporin A antagonism. 1997 Biochem. J. pmid:9581558
Fong CW et al. Specific induction of RGS16 (regulator of G-protein signalling 16) mRNA by protein kinase C in CEM leukaemia cells is mediated via tumour necrosis factor alpha in a calcium-sensitive manner. 2000 Biochem. J. pmid:11104682
Zeng B et al. Chicken FK506-binding protein, FKBP65, a member of the FKBP family of peptidylprolyl cis-trans isomerases, is only partially inhibited by FK506. 1998 Biochem. J. pmid:9461498
Bossard MJ et al. Catalytic and ligand binding properties of the FK506 binding protein FKBP12: effects of the single amino acid substitution of Tyr82 to Leu. 1994 Biochem. J. pmid:7507662
Bilmen JG et al. The inhibition of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase by macrocyclic lactones and cyclosporin A. 2002 Biochem. J. pmid:12022919
Croxtall JD et al. Differential modulation of glucocorticoid action by FK506 in A549 cells. 2003 Biochem. J. pmid:12948397
Griffiths EJ and Halestrap AP Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin. 1991 Biochem. J. pmid:1706598
Kay JE Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. 1996 Biochem. J. pmid:8670043
Omae T et al. Transient up-regulation of P-glycoprotein reduces tacrolimus absorption after ischemia-reperfusion injury in rat ileum. 2005 Biochem. Pharmacol. pmid:15670575
Woerly G et al. Demonstration of ternary immunophilin-calcineurin complexes with the immunosuppressants cyclosporin and macrolide FK506. 1994 Biochem. Pharmacol. pmid:7514409
Edkins RD et al. Comparison of cyclosporine and FK506 effects on glutathione levels in rat cochlea, brain, liver and kidney. 1992 Biochem. Pharmacol. pmid:1371687
Akool el-S et al. Cyclosporin A and tacrolimus induce renal Erk1/2 pathway via ROS-induced and metalloproteinase-dependent EGF-receptor signaling. 2012 Biochem. Pharmacol. pmid:22100870
Richter A et al. Growth inhibitory effects of FK506 and cyclosporin A independent of inhibition of calcineurin. 1995 Biochem. Pharmacol. pmid:7531976
Kraus-Friedmann N and Feng L Reduction of ryanodine binding and cytosolic Ca2+ levels in liver by the immunosuppressant FK506. 1994 Biochem. Pharmacol. pmid:7529023
Schweizer M et al. Sensitivity of mitochondrial peptidyl-prolyl cis-trans isomerase, pyridine nucleotide hydrolysis and Ca2+ release to cyclosporine A and related compounds. 1993 Biochem. Pharmacol. pmid:7680201
Henthorn DC et al. A GAL4-based yeast three-hybrid system for the identification of small molecule-target protein interactions. 2002 Biochem. Pharmacol. pmid:12007565
Campos CB et al. Ibuprofen-induced Walker 256 tumor cell death: cytochrome c release from functional mitochondria and enhancement by calcineurin inhibition. 2004 Biochem. Pharmacol. pmid:15498510
Kuromitsu S et al. 3-(13-Hydroxytridecyl)-1-[13-(3-pyridyl)tridecyl]pyridinium chloride (YM-53792), a novel inhibitor of NF-AT activation. 1997 Biochem. Pharmacol. pmid:9374420
Sigal NH et al. Observations on the mechanism of action of FK-506. A pharmacologic probe of lymphocyte signal transduction. 1990 Biochem. Pharmacol. pmid:1700909
Aicher L et al. Decrease in kidney calbindin-D 28kDa as a possible mechanism mediating cyclosporine A- and FK-506-induced calciuria and tubular mineralization. 1997 Biochem. Pharmacol. pmid:9113092
Gómez-Lechón MJ et al. The immunosuppressant drug FK506 prevents Fas-induced apoptosis in human hepatocytes. 2004 Biochem. Pharmacol. pmid:15548389
Muramoto M et al. Protective effect of FK506 against apoptosis of SH-SY5Y cells correlates with regulation of the serum inducible kinase gene. 2005 Biochem. Pharmacol. pmid:15857611
Shiraga T et al. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. 1994 Biochem. Pharmacol. pmid:7510480
Bell A et al. Roles of peptidyl-prolyl cis-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporin A, FK506, and rapamycin. 1994 Biochem. Pharmacol. pmid:7520696
Michel G et al. Antioncogene P53 and mitogenic cytokine interleukin-8 aberrantly expressed in psoriatic skin are inversely regulated by the antipsoriatic drug tacrolimus (FK506). 1996 Biochem. Pharmacol. pmid:8787547
Henke W and Jung K Comparison of the effects of the immunosuppressive agents FK 506 and cyclosporin A on rat kidney mitochondria. 1993 Biochem. Pharmacol. pmid:7690566
van Rossum HH et al. Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein 12. 2009 Biochem. Pharmacol. pmid:19154728
Vincent SH et al. Effects of the immunosuppressant FK-506 and its analog FK-520 on hepatic and renal cytochrome P450 mixed-function oxidase. 1991 Biochem. Pharmacol. pmid:1708254
Burnett D et al. Inhibition by FK506 of formyl peptide-induced neutrophil activation and associated protein synthesis. 1994 Biochem. Pharmacol. pmid:7524504
Iwata Y et al. Protective effects of Ca2+ handling drugs against abnormal Ca2+ homeostasis and cell damage in myopathic skeletal muscle cells. 2005 Biochem. Pharmacol. pmid:16009351
Forrest MJ et al. FK-506 and cyclosporin A: selective inhibition of calcium ionophore-induced polymorphonuclear leukocyte degranulation. 1991 Biochem. Pharmacol. pmid:1716098
Steinmetz RD et al. Inhibition of the functional expression of N-methyl-D-aspartate receptors in a stably transformed cell line by cyclosporin A. 2004 Biochem. Pharmacol. pmid:15242822
Tuñón MJ et al. Effects of FK506 and rapamycin on generation of reactive oxygen species, nitric oxide production and nuclear factor kappa B activation in rat hepatocytes. 2003 Biochem. Pharmacol. pmid:12907243
Doe SE et al. Early effects of the immunosuppressive drug FK-506 on signal transduction in lymphocytes. 1990 Biochem. Soc. Trans. pmid:1695581
Charters AR et al. Developmental expression of FK506 binding proteins and calcineurin in rat brain. 1995 Biochem. Soc. Trans. pmid:8566310
Charters AR et al. Immunochemical analysis of FK506 binding proteins in neuronal cell lines and rat brain. 1994 Biochem. Soc. Trans. pmid:7535258
Charters AR et al. The subcellular distribution of FK506 binding proteins in rat brain. 1994 Biochem. Soc. Trans. pmid:7535259
Fenton M and Kay JE Thapsigargin activates lymphocytes via a different pathway from ionomycin. 1993 Biochem. Soc. Trans. pmid:7510649
Pockley AG et al. Effect of cyclosporin A, FK506 and rapamycin on proliferation and soluble IL-2 receptor release from mitogenically stimulated rat spleen cells. 1995 Biochem. Soc. Trans. pmid:8654800
Hall MN The TOR signalling pathway and growth control in yeast. 1996 Biochem. Soc. Trans. pmid:8674674
Mattila PS The actions of cyclosporin A and FK506 on T-lymphocyte activation. 1996 Biochem. Soc. Trans. pmid:8674715
Ng YZ et al. Fluorescence Polarization Assay for Small Molecule Screening of FK506 Biosynthesized in 96-Well Microtiter Plates. 2017 Biochemistry pmid:28841306
Poirier SN et al. FK506 blocks intracellular Ca2+ oscillations in bovine adrenal glomerulosa cells. 2001 Biochemistry pmid:11371212
Rouviere N et al. Immunosuppressor binding to the immunophilin FKBP59 affects the local structural dynamics of a surface beta-strand: time-resolved fluorescence study. 1997 Biochemistry pmid:9200682
Galat A et al. A rapamycin-selective 25-kDa immunophilin. 1992 Biochemistry pmid:1371698
Kueppers P et al. Functional impact of a single mutation within the transmembrane domain of the multidrug ABC transporter Pdr5. 2013 Biochemistry pmid:23464591
Liu J et al. Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. 1992 Biochemistry pmid:1373650
Xu RX et al. Heteronuclear 3D NMR studies of water bound to an FK506 binding protein/immunosuppressant complex. 1993 Biochemistry pmid:7680570
Harrison RK and Stein RL Substrate specificities of the peptidyl prolyl cis-trans isomerase activities of cyclophilin and FK-506 binding protein: evidence for the existence of a family of distinct enzymes. 1990 Biochemistry pmid:1693856
Egan DA et al. Equilibrium denaturation of recombinant human FK binding protein in urea. 1993 Biochemistry pmid:7680574
Gatto GJ et al. Elucidating the substrate specificity and condensation domain activity of FkbP, the FK520 pipecolate-incorporating enzyme. 2005 Biochemistry pmid:15835888
Yem AW et al. An active FK506-binding domain of 17,000 daltons is isolated following limited proteolysis of chicken thymus hsp56. 1993 Biochemistry pmid:7504525
Main ER et al. Context-dependent nature of destabilizing mutations on the stability of FKBP12. 1998 Biochemistry pmid:9558354
Furutani M et al. FK506 binding protein from a thermophilic archaeon, Methanococcus thermolithotrophicus, has chaperone-like activity in vitro. 2000 Biochemistry pmid:10631007
Fischer S et al. A mechanism for rotamase catalysis by the FK506 binding protein (FKBP). 1993 Biochemistry pmid:7505615
Kotaka M et al. Crystal structure of the FK506 binding domain of Plasmodium falciparum FKBP35 in complex with FK506. 2008 Biochemistry pmid:18465874
Hutchison KA et al. FK506 binding to the 56-kilodalton immunophilin (Hsp56) in the glucocorticoid receptor heterocomplex has no effect on receptor folding or function. 1993 Biochemistry pmid:7682438
Craescu CT et al. Three-dimensional structure of the immunophilin-like domain of FKBP59 in solution. 1996 Biochemistry pmid:8780506
Jana B et al. Domain structure and denaturation of a dimeric Mip-like peptidyl-prolyl cis-trans isomerase from Escherichia coli. 2012 Biochemistry pmid:22263615
Yang CJ et al. Differential Large-Amplitude Breathing Motions in the Interface of FKBP12-Drug Complexes. 2015 Biochemistry pmid:26561008
Connelly PR et al. Probing hydration contributions to the thermodynamics of ligand binding by proteins. Enthalpy and heat capacity changes of tacrolimus and rapamycin binding to FK506 binding protein in D2O and H2O. 1993 Biochemistry pmid:7684925
Tai PK et al. Potentiation of progesterone receptor-mediated transcription by the immunosuppressant FK506. 1994 Biochemistry pmid:7521210
Mondragon A et al. Overexpression and purification of human calcineurin alpha from Escherichia coli and assessment of catalytic functions of residues surrounding the binuclear metal center. 1997 Biochemistry pmid:9125515
Davies TH et al. Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. 2005 Biochemistry pmid:15697228
Weiwad M et al. Comparative analysis of calcineurin inhibition by complexes of immunosuppressive drugs with human FK506 binding proteins. 2006 Biochemistry pmid:17176100
Linnert M et al. The FKBP-type domain of the human aryl hydrocarbon receptor-interacting protein reveals an unusual Hsp90 interaction. 2013 Biochemistry pmid:23418784
Rosen MK et al. Proton and nitrogen sequential assignments and secondary structure determination of the human FK506 and rapamycin binding protein. 1991 Biochemistry pmid:1709363
Solomentsev G et al. Conformational Entropy of FK506 Binding to FKBP12 Determined by Nuclear Magnetic Resonance Relaxation and Molecular Dynamics Simulations. 2018 Biochemistry pmid:29412644
Cañadas O et al. Characterization of liposomal tacrolimus in lung surfactant-like phospholipids and evaluation of its immunosuppressive activity. 2004 Biochemistry pmid:15274647
Lepre CA et al. Solution structure of FK506 bound to the R42K, H87V double mutant of FKBP-12. 1994 Biochemistry pmid:7524662
Tai PK et al. P59 (FK506 binding protein 59) interaction with heat shock proteins is highly conserved and may involve proteins other than steroid receptors. 1993 Biochemistry pmid:7689858
Cheng JW et al. 15N NMR relaxation studies of the FK506 binding protein: backbone dynamics of the uncomplexed receptor. 1993 Biochemistry pmid:7690248
Weininger U et al. Dynamics of Aromatic Side Chains in the Active Site of FKBP12. 2017 Biochemistry pmid:27936610
DiLella AG and Craig RJ Exon organization of the human FKBP-12 gene: correlation with structural and functional protein domains. 1991 Biochemistry pmid:1716149
Nielsen JB et al. Biosynthesis of the immunosuppressant immunomycin: the enzymology of pipecolate incorporation. 1991 Biochemistry pmid:2043618
Meadows RP et al. Three-dimensional structure of the FK506 binding protein/ascomycin complex in solution by heteronuclear three- and four-dimensional NMR. 1993 Biochemistry pmid:7678499
Cheng JW et al. 15N NMR relaxation studies of the FK506 binding protein: dynamic effects of ligand binding and implications for calcineurin recognition. 1994 Biochemistry pmid:7512379
Shadidy M et al. Biochemical analysis of mouse FKBP60, a novel member of the FKPB family. 1999 Biochim. Biophys. Acta pmid:10524204
Raufman JP et al. Regulation of calcium-induced exocytosis from gastric chief cells by protein phosphatase-2B (calcineurin). 1997 Biochim. Biophys. Acta pmid:9202177
Karlsson H et al. Energy levels in resting and mitogen-stimulated human lymphocytes during treatment with FK506 or cyclosporin A in vitro. 1997 Biochim. Biophys. Acta pmid:9131051
Chen Z et al. Mutations adjacent to the end of transmembrane helices 6 and 7 independently affect drug efflux capacity of yeast ABC transporter Pdr5p. 2014 Biochim. Biophys. Acta pmid:24333836
Faralli JA et al. Dexamethasone increases αvβ3 integrin expression and affinity through a calcineurin/NFAT pathway. 2013 Biochim. Biophys. Acta pmid:24100160
Ozawa T Elucidation of the ryanodine-sensitive Ca2+ release mechanism of rat pancreatic acinar cells: modulation by cyclic ADP-ribose and FK506. 2004 Biochim. Biophys. Acta pmid:15363629
Hendrych T et al. Characterization of the kinetics and mechanisms of inhibition of drugs interacting with the S. cerevisiae multidrug resistance pumps Pdr5p and Snq2p. 2009 Biochim. Biophys. Acta pmid:19111673
Stasik I et al. Ionomycin-induced apoptosis of thymocytes is independent of Nur77 NBRE or NurRE binding, but is accompanied by Nur77 mitochondrial targeting. 2007 Biochim. Biophys. Acta pmid:17588685
Yu L and Fesik SW pH titration of the histidine residues of cyclophilin and FK506 binding protein in the absence and presence of immunosuppressant ligands. 1994 Biochim. Biophys. Acta pmid:7524680
López E et al. FKBP52 is involved in the regulation of SOCE channels in the human platelets and MEG 01 cells. 2013 Biochim. Biophys. Acta pmid:23228564
Miyamoto S et al. Signal transduction pathways that contribute to increased protein synthesis during T-cell activation. 2000 Biochim. Biophys. Acta pmid:11072066
Swartz DJ et al. P-glycoprotein is fully active after multiple tryptophan substitutions. 2013 Biochim. Biophys. Acta pmid:23261390
Ãœnal CM and Steinert M FKBPs in bacterial infections. 2015 Biochim. Biophys. Acta pmid:25529296
Cen J et al. The new immunosuppressant, isogarcinol, binds directly to its target enzyme calcineurin, unlike cyclosporin A and tacrolimus. 2015 Biochimie pmid:25701551
Allen C et al. Polycaprolactone-b-poly(ethylene oxide) block copolymer micelles as a novel drug delivery vehicle for neurotrophic agents FK506 and L-685,818. 1998 Sep-Oct Bioconjug. Chem. pmid:9736490
Tamura T et al. A quantitative analysis and chemical approach for the reduction of nonspecific binding proteins on affinity resins. 2003 Nov-Dec Bioconjug. Chem. pmid:14624639
DaSilva I et al. Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain. 2017 BioDrugs pmid:28534103
Keating GM and Lyseng-Williamson KA Everolimus: a guide to its use in liver transplantation. 2013 BioDrugs pmid:23696253
Patel JK and Kobashigawa JA Tacrolimus in heart transplant recipients: an overview. 2007 BioDrugs pmid:17516709
Zhai J et al. Tacrolimus in the treatment of ocular diseases. 2011 BioDrugs pmid:21443273
Quesniaux VF Immunosuppressants: tools to investigate the physiological role of cytokines. 1993 Bioessays pmid:7507316
Cheng C et al. MARD: a new method to detect differential gene expression in treatment-control time courses. 2006 Bioinformatics pmid:16928738
Koreth J et al. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. 2015 Biol. Blood Marrow Transplant. pmid:26055298